香蕉视频

A new study shows that breast cancers that become resistant to hormone therapy have different patterns of estrogen receptor binding. Breast cancers may become resistant to standard hormone therapy because the estrogen receptor becomes reprogrammed to bind to different spots in the genome, according to a study publishing (January 4) in Nature. The findings could provide clues for developing therapies to overcome resistance or diagnostics that could predict which patients are more likely to be resistant to hormone therapy.

If FOXA1 is the guilty party, however, targeting the protein with drugs early on in breast cancer therapy may one day help prevent resistance, said Vincent Giguere of 香蕉视频, who wrote a Nature News and Views piece about the paper.

鈥淚f you can stop the reprogramming early, then the tumor will not go from a good outcome to a bad outcome.鈥� If the findings can be validated in a larger cohort of tumor samples, he added, researchers could also use estrogen receptor binding patterns to predict outcome in patients.